NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 17 March 2022, 09:30am

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Dr Sanjeev Patel (Vice Chair) Present for all items
3. Mr Baljit Singh Present for all items
4. Ms Anna Pracz Present for all items
5. Mr Gabriel Rogers Present for all items
6. Professor Iolo Doull Present for all items
7. Dr James Fotheringham Present for all items
8. Mrs Laura Bojke Present for items 1 to 6.1.3
9. Mrs Maria Bretzitski Present for items 1 to 5.3.2
10. Ms Mary Weatherstone Present for all items
11. Dr Nicholas Latimer Present for all items
12. Professor Nicky Welton Present for all items
13. Mr Nigel Westwood Present for all items
14. Mr Peter Wheatley-Price Present for items 1 to 4.3.2, 6 to 6.3.2
15. Dr Rhiannon Owen Present for all items
16. Dr Stephen Smith Present for all items
17. Dr Stuart Williams Present for items 1 to 5.3.2
18. Mr Tony Wootton Present for all items

NICE staff present

Henry Edwards, Associate Director Present for items 1 to 5.3.2

Janet Robertson, Associate Director Present for items 6 to 6.2.2

Jeremy Powell, Project Manager Present for 1 to 5.3.2

Thomas Feist, Project Manager Present for items 6 to 6.2.2

Nicola Bodey, Senior Business Analyst Resource Impact Assessment. Present for items 1 to 5.1.3

Adam Brooke, Technical Advisor Present for 1 to 4.3.2

Michelle Green, Technical Advisor Present for items 6 to 6.2.2

Ying-Ying Wang, Technical Analyst Present for 1 to 4.3.2

Harsimran Sarpal, Technical Analyst Present for items 6 to 6.2.2

Catrin Austin, Technical Analyst Present for 1 to 4.3.2

Rufaro Kausi, Health Technology Assessment Advisor Present for items 6 to 6.2.2

George Millington, Health Technology Assessment Analyst Present for 1 to 4.3.2

George Braileanu, Health Technology Assessment Analyst Present for items 6 to 6.2.2

Steven Norton, Health Technology Assessment Analyst Present for 1 to 4.3.2

Emily Eaton-Turner, Technical Advisor, Commercial Risk Present for 1 to 4.3.2, 6 to 6.2.2

Catherine Pank, Assistant Project Manager, COT Present for items 5 to 6.1.2

Laura Marsden, Advisor, PiP Present for items 1 to 4.1.3, 5 to 5.1.3 & 6 to 6.1.3

Lucinda Evans, Coordinator, MiP Present for items 1 to 5.3.2

Lyn Davies, Coordinator, MiP Present for 1 to 4.1.3, 6 to 6.1.3

Gemma Smith, Coordinator, COT Present for items 5 to 5.3.2

Laura Kelly, Administrator, COT Present for all items

Rumana Zaman, Administrator, Project Team Present for 1 to 5.3.2

Marcia Miller, Administrator, Project Team Present for 6 to 6.1.3

External assessment group representatives present

Tracey Jhita, BMJ Group Present for items 1 to 4.2.1

Charlotta Karner, BMJ Group Present for items 1 to 4.2.1

Sabine Grimm, Kleijnen Systematic Reviews Ltd (KSR) Present for items 5 to 5.2.1

Nigel Armstrong, Kleijnen Systematic Reviews Ltd (KSR) Present for items 5 to 5.2.1

Jeremy Howick, Kleijnen Systematic Reviews Ltd (KSR) Present for items 6 to 6.1.3

Experts present

Mr Andrew Proctor, Chief Executive, National Eczema Society. Present for items 1 to 4.1.3

Mrs Christine Roxburgh, Patient, Eczema Outreach Support. Present for items 1 to 4.1.3

Professor Anthony Bewley, Consultant Dermatologist, Barts Health NHS Present for item 4.1.3

Dr Jane Ravenscroft, Consultant Dermatologist, Nottingham University Hospitals NHS Trust. Present for items 1 to 4.1.3

Mrs Rachel Meadows, Patient Expert, Nominated by Crohn’s & Colitis UK. Present for items 5 to 5.1.3

Ms Ruth Wakeman, Director of Services, Advocacy & Evidence, Crohn’s & Colitis UK. Present for items 5 to 5.1.3

Ms Anja St Clair Jones, Consultant Pharmacist Brighton and Sussex University Hospitals NHS Trust. Present for items 5 to 5.1.3

Dr Gordon Moran, Associate Professor in Gastroenterology University of Nottingham/Nottingham Hospitals. Present for items 5 to 5.1.3

Professor Jonathan Barrett, Mayer Professor of Renal Medicine, University of Leicester. Present for items 6 to 6.1.3

Professor Sunil Bhandari, Consultant Nephrologist Hull University Teaching Hospitals NHS Trust. Present for items 6 to 6.1.3

Mr Guy Hill, Patient, Nominated by Kidney Care UK. Present for items 6 to 6.1.3

NICE Observers present

Caron Jones, HTA Advisor, NICE Present for items 1 to 4.3.2

Emilene Coventry, Senior Medical Editor, NICE Present for items 6 to 6.2.2

Anna Sparshatt, Senior Medical Editor, NICE Present for items 6 to 6.2.2

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Ms Denise Bryceland, Dr Mark Glover, Dr Toby Smith & Dr Veline L’ Esperance.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 17 February 2022.

### Appraisal of Upadacitinib, abrocitinib and tralokinumab for dermatitis [ID3960]

* 1. Part 1 – Open session
     1. The chair welcomed the invited professional experts, external assessment group representatives, members of the public and company representatives from Pfizer, Abbvie & Leo Pharma.
     2. The chair asked all committee members, professional experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr James Fotheringham declared a direct financial interest, as he has participated in an advisory board on risk prediction models in kidney transplantation - honorarium paid directly to himself (Novartis Pharmaceuticals (ciclosporin, mycophenolate mofetil) – not participating.) It was agreed that this declaration would not prevent Dr Fotheringham from participating in the discussion.
* Dr Nicholas Latimer declared a direct financial interest, as in October 2021 he was paid to give Novartis staff a training session on survival analysis. This was not product or appraisal specific and was about methods. Novartis are listed as a comparator company who is not participating. As of May 2021, Dr Latimer has been a member of the ScHARR team for a consultancy project involving the adjustment for treatment switching observed in the NETTER-1 trial, comparing lutathera to best supportive care alone in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumours. Lutathera is made by Advanced Accelerator Applications (AAA) Ltd, a Novartis company. Novartis are listed as a comparator company who is not participating. It was agreed that these declarations would not prevent Dr Latimer from participating in the discussion.
* Christine Roxburgh declared an indirect financial interest, as her organisation (Eczema Support Outreach) has received funding towards the work of the charity from AbbVie and Pfizer, and funding towards the charity’s online resources from Leo Pharma. It was agreed that this declaration would not prevent Christine Roxburgh from participating in the discussion
* Andrew Proctor declared an indirect financial interest, as AbbVie, Leo Pharma and comparator companies Sanofi and Eli Lilly & Co, have been corporate members of National Eczema Society over the past 12 months, and the fees paid for this membership aid in funding the charity’s core operating costs. The Society’s Corporate Membership Scheme complies with the ABPI code of practice and allows company partners to demonstrate public support for the important work of the Society. It was agreed that this declaration would not prevent Andrew Proctor from participating in this discussion.
* Professor Anthony Bewley declared a direct financial interest, as he has carried out ad hoc consultancy with Abbvie, Almirall, Galderma, Lilly, Leo Pharma, Janssen, Novartis, Sanofi and UCB and, has received recent travel grants (AAD/BAD/EADV) from Galderma and Leo Pharma. Professor Bewley also declared an indirect financial interest as EADV received research grants for the following publications: Practical Psychodermatology (2014, Wiley) Clinical Psychodermatology (Springer 2021.) Professor Bewley also declared a personal non-financial interest, as he has participated in ad hoc webinar and training events with Abbvie, Almirall, Galderma, Lilly, Leo Pharma, Janssen, Novartis, Sanofi, and UCB and is involved in expert functions in health care and health guidance processes for the following: Treasurer British Association of Dermatologists, President Dowling Club 2019-20, Chair Psychodermatology UK 2008-20, Secretary European Society of Dermatology and Psychiatry, Chair of APPGOS, Advisory, Psoriasis Association, Changing Faces, ISG, NES. It was agreed that these declarations would not prevent Professor Bewley from participating in this discussion
  + 1. The Chair led a discussion of the consultation comments presented to the committee.This information was presented to the committee by Maria Bretzitski, Stephen Smith and Nigel Westwood.
  1. Part 2a – Closed session (members of the public, experts and company representatives were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10856>

### Appraisal of Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]

* 1. Part 1 – Open session
     1. The chair welcomed the invited professional experts, external assessment group representatives, members of the public and company representatives from Galapagos Biotech Ltd.
     2. The chair asked all committee members, professional and patient experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor Nicky Welton declared an indirect financial interest as she delivered a training course to Takeda (comparator company) in Aug 2021. The training was purely methodological and unrelated to any technology and the payment was received by Nicky Welton’s organisation, not paid to her directly. It was agreed that would not prevent Professor Welton from participating in the discussion.
* Dr Nicholas Latimer declared a direct financial interest, as of October 2021, Nicholas has been a member of the ScHARR team for a research project investigating methods for adjusting for treatment switching in clinical trials, funded by Merck, Sharpe and Dohme. This is not drug or appraisal specific and is about developing methods. Merck, Sharpe and Dohme are listed as a comparator who is not participating. It was agreed that this declaration would not prevent Dr Latimer from participating in the discussion.
* Gabriel Rogers declared an indirect non-financial interest, as a former employee of NICE, Gabriel was the health economic modeller for the 2019 update of the ulcerative colitis guideline (NG130), which partially defines the treatment pathway into which filgotinib is proposed to fit. It was agreed this conflict would not prevent Gabriel Rogers from participating in this discussion.
* Nigel Westwood declared an indirect non-financial interest, as he sat as a lay member on the Guideline Development Committee for Ulcerative colitis: management (CG166). Nigel has previously been a trustee and vice-chair (2005 – 2010) of Crohn's and Colitis UK. It was agreed this conflict would not prevent Nigel Westwood from participating in this discussion.
* Peter Wheatley-Price declared a direct financial interest prior to the meeting, as Takeda Manufacture vedolizumab which is used in this indication and listed as a comparator. This a key asset for Takeda locally, and therefore it was agreed this conflict would prevent Peter Wheatley-Price from participating in this discussion.
* Ruth Wakeman declared an indirect financial interest, as Crohn’s & Colitis UK have received funding from Galapagos Biotech Ltd. It was agreed that this declaration would not prevent Ruth Wakeman from attending this discussion.
  + 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Baljit Singh, Rhiannon Owen and Tony Wootton.
  1. Part 2a – Closed session (members of the public, experts and company representatives were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10600>

### Appraisal of Roxadustat for treating anaemia in people with chronic kidney disease [ID1483]

* 1. Part 1 – Open session
     1. The chair welcomed the invited professional experts, external assessment group representatives, members of the public and company representatives from Astellas.
     2. The chair asked all committee members, professional experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor Sunil Bhandari declared a direct financial interest, as he has received honorarium for lecturing and attending advisory boards from companies who produce medications for treating anaemia of chronic kidney disease including Astellas, an AstraZeneca advisory board, and a GSK advisory Board in relation to HIF stabilizers. It was agreed that this declaration would not prevent Professor Bhandari from participating in the discussion.
* Professor Jonathan Barrett declared a direct financial interest, as he has received payments from Astellas for speaking engagements and sitting on advisory boards. It was agreed that this declaration would not prevent Professor Barrett from participating in the discussion.
  + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, professional and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the documents in line with their decisions and further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10610>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 14 April 2022 and will start promptly at 09:30am.